[1]
|
Bota, D.A., Desjardins, A., Quinn, J.A., Affronti, M.L. and Friedman, H.S. (2007) Interstitial Chemotherapy with Biodegradable BCNU (Gliadel®) Wafers in the Treatment of Malignant Gliomas. Therapeutics & Clinical Risk Management, 3, 707-715.
|
[2]
|
唐慰慈. 亚硝基脲类抗癌药物[J]. 药学学报, 1982, 17(6): 472-479.
|
[3]
|
Ueda-Kawamitsu, H., Lawson, T.A. and Gwilt, P.R. (2002) In Vitro Pharmacokinetics and Pharmacodynamics of 1,3-Bis(2-chloroethyl)-nitrosourea (BCNU). Biochemical Pharmacology, 63, 1209-1218.
https://doi.org/10.1016/S0006-2952(02)00878-X
|
[4]
|
Penketh, P.G., Shyam, K. and Sartorelli, A.C. (2000) Comparison of DNA Lesions Produced by Tumor Inhibitory 1,2-Bis(sulfonyl)hydrazines and Chloroethylnitrosoureas. Biochemical Pharmacology, 59, 283-291.
https://doi.org/10.1016/S0006-2952(99)00328-7
|
[5]
|
Engelhard, H.H. (2000) The Role of Interstitial BCNU Chemotherapy in the Treatment of Malignant Glioma. Surgical Neurology, 53, 458-464. https://doi.org/10.1016/S0090-3019(00)00211-1
|
[6]
|
章文斌, 马晓东, 周定标. BCNU缓释制剂的研究进展[J]. 中国微侵袭神经外科杂志, 2005, 10(4): 189-192.
|
[7]
|
Tamargo, R.J., Myseros, J.S., Epstein, J.I., Yang, M.B., Chasin, M. and Brem, H. (1993) Interstitial Chemotherapy of the 9L Gliosarcoma: Controlled Release Polymers for Drug Delivery in the Brain. Cancer Research, 53, 329-333.
|
[8]
|
Domb, A.J., Israel, Z.H., Elmalak, O., Teomim, D. and Bentolila, A. (1999) Preparation and Characterization of Carmustine Loaded Polyanhydride Wafers for Treating Brain Tumors. Pharmaceutical Research, 16, 762-765.
https://doi.org/10.1023/A:1011995728760
|
[9]
|
Pereira, D.Y., Yip, A.T., Lee, B.S. and Kamei, D.T. (2014) Modeling Mass Transfer from Carmustine-Loaded Polymeric Implants for Malignant Gliomas.Journal of Laboratory Automation, 19, 19-34.
https://doi.org/10.1177/2211068213499157
|
[10]
|
Kleinberg, L. (2016) Polifeprosan 20, 3.85% Carmustine Slow Release Wafer in Malignant Glioma: Patient Selection and Perspectives on a Low-Burden Therapy. Patient Preference and Adherence, 10, 2397-2406.
https://doi.org/10.2147/PPA.S93020
|
[11]
|
Shive, M.S. and Anderson, J.M. (2012) Biodegradation and Biocompatibility of PLA and PLGA Microspheres. Advanced Drug Delivery Reviews, 64, 5-24.
|
[12]
|
Lee, J.S., An, T.K., Chae, G.S., Jeong, J.K., Cho, S.H., Lee, H.B. and Khang, G. (2005) Evaluation of In Vitro and In Vivo Antitumor Activity of BCNU-Loaded PLGA Wafer against 9L Gliosarcoma. European Journal of Pharmaceutics & Biopharmaceutics, 59, 169-175. https://doi.org/10.1016/j.ejpb.2004.06.006
|
[13]
|
Zhu, T.M., Shen, Y.W., Tang, Q.S., Chen, L.P., Gao, H.S. and Zhu, J.H. (2014) BCNU/PLGA Microspheres: A Promising Strategy for the Treatment of Gliomas in Mice. Chinese Journalof Cancer Research, 26, 81-88.
|
[14]
|
Xu, X., Chen, X., Xu, X., Lu, T., Wang, X., Yang, L. and Jing, X. (2006) BCNU-Loaded PEG-PLLA Ultrafine Fibers and Their In Vitro Antitumor Activity against Glioma C6 Cells. Journal of Controlled Release, 114, 307-316.
https://doi.org/10.1016/j.jconrel.2006.05.031
|
[15]
|
Lu, Y.J., Yang, H.W., Hung, S.C., Huang, C.Y., Li, S.M., Ma, C.C., Chen, P.Y., Tsai, H.C., Wei, K.C. and Chen, J.P. (2012) Improving Thermal Stability and Efficacy of BCNU in Treating Glioma Cells Using PAA-Functionalized Graphene Oxide. International Journal of Nanomedicine, 7, 1737-1747.
|
[16]
|
Kim, M.S., Seo, K.S., Seong, H.S., Cho, S.H., Lee, H.B., Hong, K.D., Kim, S.K. and Khang, G. (2005) Synthesis and Characterization of Polyanhydride for Local BCNU Delivery Carriers. Bio-Medical Materials and Engineering, 15, 229-238.
|
[17]
|
Li, Y., Ho Duc, H.L., Tyler, B., Williams, T., Tupper, M., Langer, R., Brem, H. and Cima, M.J. (2005) In Vivo Delivery of BCNU from a MEMS Device to a Tumor Model. Journal of Controlled Release, 106, 138-145.
https://doi.org/10.1016/j.jconrel.2005.04.009
|
[18]
|
Alexandru, D., Linskey, M.E., Kim, R.C. and Bota, D.A. (2013) Undifferen-tiated Sarcoma Induced by BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) Wafers. Journal of Interdisciplinary Histopathology, 1, 163-167.
https://doi.org/10.5455/jihp.20130116012102
|
[19]
|
Sukumari-Ramesh, S., Prasad, N., Alleyne Jr., C.H., Vender, J.R. and Dhandapani, K.M. (2015) Overexpression of Nrf2 Attenuates Carmustine-Induced Cytotoxicity in U87MG Human Glioma Cells. BMC Cancer, 15, 118-127.
https://doi.org/10.1186/s12885-015-1134-z
|
[20]
|
Figueiredo, E.G., Faria, J.W. and Teixeira, M.J. (2010) Treatment of Recurrent Glioblastoma with Intra-Arterial BCNU [1,3-bis(2-chloroethyl)-1-nitrosourea]. Arquivos de Neuro-Psiquiatria, 68, 778-782.
https://doi.org/10.1590/S0004-282X2010000500020
|
[21]
|
Reithmeier, T., Graf, E., Piroth, T., Trippel, M., Pinsker, M.O. and Nikkhah, G. (2010) BCNU for Recurrent Glioblastoma Multiforme: Efficacy, Toxicity and Prognostic Factors. BMC Cancer, 10, 30-36.
https://doi.org/10.1186/1471-2407-10-30
|
[22]
|
Jungk, C., Chatziaslanidou, D., Ahmadi, R., Capper, D., Bermejo, J.L., Exner, J., von Deimling, A., Herold-Mende, C. and Unterberg, A. (2016) Chemotherapy with BCNU in Recurrent Glioma: Analysis of Clinical Outcome and Side Effects in Chemotherapy-Naïve Patients. BMC Cancer, 16, 81-91. https://doi.org/10.1186/s12885-016-2131-6
|
[23]
|
Ene, C.I., Nerva, J.D., Morton, R.P., Barkley, A.S., Barber, J.K., Ko, A.L. and Silbergeld, D.L. (2016) Safety and Efficacy of Carmustine (BCNU) Wafers for Metastatic Brain Tumors. Surgical Neurology Inter-national, 7, S295-S299.
https://doi.org/10.4103/2152-7806.181987
|
[24]
|
Zackheim, H.S. (2003) Topical Carmustine (BCNU) in the Treatment of Mycosis Fungoides. Dermatologic Therapy, 16, 299-302. https://doi.org/10.1111/j.1396-0296.2003.01641.x
|
[25]
|
MacArthur, K.M., Jariwala, N., Kim, E.J. and Rook, A.H. (2017) Topical Carmustine as Monotherapy or as Multimodality Therapy for Folliculotropic Mycosis Fungoides. Acta Dermato-Venereologica, 97, 373-374.
https://doi.org/10.2340/00015555-2551
|
[26]
|
高玉杰. 卡莫司汀及全脑预防照射对缓解期小细胞肺癌脑转移预防作用的疗效观察及预后相关性分析[D]: [硕士学位论文]. 大连: 大连医科大学, 2013.
|
[27]
|
Mokhtari, R.B., Homayouni, T.S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B. and Yeger, H. (2017) Combination Therapy in Combating Cancer. Oncotarget, 8, 38022-38043. https://doi.org/10.18632/oncotarget.16723
|
[28]
|
Vogelhuber, W., Spruss, T., Bernhardt, G., Buschauer, A. and Göpferich, A. (2002) Efficacy of BCNU and Paclitaxel Loaded Subcutaneous Implants in the Interstitial Chemotherapy of U-87 MG Human Glioblastoma Xenografts. International Journal of Pharmaceutics, 238, 111-121. https://doi.org/10.1016/S0378-5173(02)00061-3
|
[29]
|
Lonser, R.R., Sarntinoranont, M., Morrison, P.F. and Oldfield, E.H. (2015) Convection-Enhanced Delivery to the Central Nervous System. Journal of Neurosurgery, 122, 697-706. https://doi.org/10.3171/2014.10.JNS14229
|
[30]
|
Zhan, W., Arifin, D.Y., Lee, T.K. and Wang, C.H. (2017) Mathematical Mod-elling of Convection Enhanced Delivery of Carmustine and Paclitaxel for Brain Tumour Therapy. Pharmaceutical Research, 34, 860-873.
https://doi.org/10.1007/s11095-017-2114-6
|
[31]
|
Thamilselvan, V., Menon, M. and Thamilselvan, S. (2016) Combination of Carmustine and Selenite Effectively Inhibits Tumor Growth by Targeting Androgen Receptor, Androgen Receptor-Variants, and Akt in Preclinical Models: New Hope for Patients with Castration Resistant Prostate Cancer. International Journal of Cancer, 139, 1632-1647.
https://doi.org/10.1002/ijc.30189
|
[32]
|
Thamilselvan, V., Menon, M., Stein, G.S., Valeriote, F. and Thamilselvan, S. (2017) Combination of Carmustine and Selenite Inhibits EGFR Mediated Growth Signaling in Androgen-Independent Prostate Cancer Cells. Journal of Cellular Biochemistry, 118, 4331-4340. https://doi.org/10.1002/jcb.26086
|
[33]
|
Azzalin, A., Nato, G., Parmigiani, E., Garello, F., Buffo, A. and Magrassi, L. (2017) Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas. Neoplasia, 19, 364-373.
https://doi.org/10.1016/j.neo.2017.02.009
|
[34]
|
Krishnan, A.Y., Palmer, J., Nademanee, A.P., Chen, R., Popplewell, L.L., Tsai, N.C., Sanchez, J.F., Simpson, J., Spielberger, R. and Yamauchi, D. (2017) Phase II Study of Yttrium-90 Ibritumomab Tiuxetan plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology. Biology of Blood and Marrow Transplantation, 23, 922-929. https://doi.org/10.1016/j.bbmt.2017.03.004
|
[35]
|
孔庆忠, 张红军. 一种同载卡莫司汀和氟尿嘧啶的抗癌缓释剂[P]. CN: 2007.CN100998558A.
|